The DOI matches its Crossref record; 279 of the 279 references it cites were found in a registry or an index.
CYP2C9 Genotype-guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study
Abstract
Warfarin anticoagulation effect is characterized by marked variability, some of which has been attributed to CYP2C9 polymorphisms. This study prospectively examines whether a priori knowledge of CYP2C9 genotype may improve warfarin therapy. Patients were randomly assigned to receive warfarin by a validated algorithm ("control", 96 patients) or CYP2C9 genotype-adjusted algorithms ("study", 95 patients). The first therapeutic international normalized ratio and stable anticoagulation were reached 2.73 and 18.1 days earlier in the study group, respectively (P<0.001). The faster rate of initial anticoagulation was driven by a 28% higher daily dose in the study group (P<0.001). Study group patients spent more time within the therapeutic range (80.4 vs 63.4%, respectively, P<0.001) and experienced less minor bleeding (3.2 vs 12.5%, P<0.02, respectively). In conclusion, CYP2C9 genotype-guided warfarin therapy is more efficient and safer than the "average-dose" protocol. Future research should focus on construction of algorithms that incorporate other polymorphisms (VKORC1), host factors, and environmental influences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790 · cited 1×
“[79-82] In addition, the frequency of HLA-B*1502 is higher in South Asians, including Taiwanese, Hong Kong Chinese, Thai, and Indians (8-11%), than in North Asians, such as Beijing Chinese, Japanese, and Koreans (1-2%).”
BackgroundShimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
Systematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809171 · Cited by 2,497
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y.-M., Szumlanski, C. L., & Weinshilboum, R. M. (1996) · Pharmacogenetics · doi:10.1097/00008571-199606000-00007 · Cited by 1,788
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., Steg, P. G., Ferrières, J., Danchin, N., & Becquemont, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808227 · Cited by 1,728
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809329 · Cited by 1,577
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L., & Rettie, A. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044503 · Cited by 1,399
Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation
Hylek, E. M., Go, A. S., Chang, Y., Jensvold, N. G., Henault, L. E., Selby, J. V., & Singer, D. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022913 · Cited by 1,277
Aithal, G. P., Day, C. P., Kesteven, P. J., & Daly, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04474-2 · Cited by 1,243
Weinshilboum, R. M., & Sladek, S. L. (1980) · PubMed · Cited by 1,195
Lotta, T., Vidgren, J., Tilgmann, C., Ulmanen, I., Melen, K., Julkunen, I., & Taskinen, J. (1995) · Biochemistry · doi:10.1021/bi00013a008 · Cited by 1,167
Systematic overview of warfarin and its drug and food interactions
Holbrook, A. M. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1095 · Cited by 1,160 · cited 1×
“Notably, a large fraction of the patients who entered the study suffered from various chronic illnesses and accordingly were treated by a median of 5 drugs (interquartile range from 2 to 8 drugs), including a median of 1 drug (interquartile range from 1 to 2 drugs) likely to alter the anticoagulant effect of warfarin.…”
BackgroundMechanism-Based Concepts of Size and Maturity in Pharmacokinetics
Anderson, B. J., & Holford, N. H. G. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094708 · Cited by 1,125
Ingelman-Sundberg, M. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500285 · Cited by 1,108
Kearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Higashi, M. K. (2002) · JAMA · doi:10.1001/jama.287.13.1690 · Cited by 1,048
Hagenbuch, B., & Meier, P. J. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1168-y · Cited by 1,019
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action
Shu, Y., Sheardown, S. A., Brown, C., Owen, R. P., Zhang, S., Castro, R. A., Ianculescu, A. G., Yue, L., Lo, J. C., Burchard, E. G., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30558 · Cited by 967
Collet, J.-P., Hulot, J.-S., Pena, A., Villard, E., Esteve, J.-B., Silvain, J., Payot, L., Brugier, D., Cayla, G., Beygui, F., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61845-0 · Cited by 967
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
The Human Hepatic Cytochromes P450 Involved in Drug Metabolism
Wrighton, S. A., & Stevens, J. C. (1992) · Critical Reviews in Toxicology · doi:10.3109/10408449209145319 · Cited by 944
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
Hulot, J.-S. (2006) · Blood · doi:10.1182/blood-2006-04-013052 · Cited by 931
Risk Factors for Intracranial Hemorrhage in Outpatients Taking Warfarin
Hylek, E. M., & Singer, D. E. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-11-199406010-00001 · Cited by 919
American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy
Hirsh, J., Fuster, V., Ansell, J., & Halperin, J. L. (2003) · Circulation · doi:10.1161/01.cir.0000063575.17904.4e · Cited by 911
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
Marzolini, C. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.012 · Cited by 895
Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention
Landefeld, C. S., & Beyth, R. J. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90285-w · Cited by 893
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Beutler, E., Gelbart, T., & Demina, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8170 · Cited by 853
Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin
Gage, B., Eby, C., Johnson, J., Deych, E., Rieder, M., Ridker, P., Milligan, P., Grice, G., Lenzini, P., Rettie, A., et al. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.10 · Cited by 847
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
Miners, J. O., & Birkett, D. J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00721.x · Cited by 844
Ding, X., & Kaminsky, L. S. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140251 · Cited by 822
Human P450 metabolism of warfarin
Kaminsky, L. S., & Zhang, Z.-Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00140-4 · Cited by 798
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
Zanger, U. M., Raimundo, S., & Eichelbaum, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0832-2 · Cited by 795
Landefeld, C. S., & Goldman, L. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90564-0 · Cited by 778
BRANDT, J. T., CLOSE, S. L., ITURRIA, S. J., PAYNE, C. D., FARID, N. A., ERNEST, C. S., LACHNO, D. R., SALAZAR, D., & WINTERS, K. J. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02775.x · Cited by 734
Relling, M. V., Hancock, M. L., Rivera, G. K., Sandlund, J. T., Ribeiro, R. C., Krynetski, E. Y., Pui, C.-H., & Evans, W. E. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.23.2001 · Cited by 733
SIM, S., RISINGER, C., DAHL, M., AKLILLU, E., CHRISTENSEN, M., BERTILSSON, L., & INGELMANSUNDBERG, M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.002 · Cited by 732
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Iyer, L., Das, S., Janisch, L., Wen, M., Ramírez, J., Karrison, T., Fleming, G. F., Vokes, E. E., Schilsky, R. L., & Ratain, M. J. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500072 · Cited by 720
Ingelman-Sundberg, M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.02.007 · Cited by 676
The genetic determinants of the CYP3A5 polymorphism
Hustert, E., Haberl, M., Burk, O., Wolbold, R., He, Y.-Q., Klein, K., Nuessler, A. C., Neuhaus, P., Klattig, J., Eiselt, R., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200112000-00005 · Cited by 673
Risk Factors for Complications of Chronic Anticoagulation: A Multicenter Study
Fihn, S. D., McDonell, M., Martin, D., Henikoff, J., Vermes, D., Kent, D., White, R. H., & for the Warfarin Optimized Outpatient Follow-up Study Group* (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-7-199304010-00005 · Cited by 671
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
Lennard, L., Lilleyman, J. S., Van Loon, J., & Weinshilboum, R. M. (1990) · The Lancet · doi:10.1016/0140-6736(90)91745-v · Cited by 651
Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., Sjöqvist, F., & Ingelman-Sundberg, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11825 · Cited by 644
Enzymology of human cytosolic sulfotransferases
Falany, C. N. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.4.9068609 · Cited by 604
Lennard, L., Van Loon, J. A., & Weinshilboum, R. M. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.119 · Cited by 593
Why Do Patients With Atrial Fibrillation Not Receive Warfarin?
Bungard, T. J., Ghali, W. A., Teo, K. K., McAlister, F. A., & Tsuyuki, R. T. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.1.41 · Cited by 593
Managing Oral Anticoagulant Therapy
Ansell, J., Hirsh, J., Dalen, J., Bussey, H., Anderson, D., Poller, L., Jacobson, A., Deykin, D., & Matchar, D. (2001) · Chest · doi:10.1378/chest.119.1_suppl.22s · Cited by 572
The largest prospective warfarin-treated cohort supports genetic forecasting
Wadelius, M., Chen, L. Y., Lindh, J. D., Eriksson, N., Ghori, M. J. R., Bumpstead, S., Holm, L., McGinnis, R., Rane, A., & Deloukas, P. (2009) · Blood · doi:10.1182/blood-2008-04-149070 · Cited by 550
Weinshilboum, R. M., Otterness, D. M., & Szumlanski, C. L. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.19 · Cited by 549
Fang, M. C., Chang, Y., Hylek, E. M., Rosand, J., Greenberg, S. M., Go, A. S., & Singer, D. E. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00005 · Cited by 532
Johnson, T. N., Rostami-Hodjegan, A., & Tucker, G. T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645090-00005 · Cited by 530
The SLC22 drug transporter family
Koepsell, H., & Endou, H. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1089-9 · Cited by 525
Nishizato, Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00060-2 · Cited by 511
Transporters and drug therapy: Implications for drug disposition and disease
HO, R., & KIM, R. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.05.011 · Cited by 502
Dai, D., Zeldin, D. C., Blaisdell, J. A., Chanas, B., Coulter, S. J., Ghanayem, B. I., & Goldstein, J. A. (2001) · Pharmacogenetics · doi:10.1097/00008571-200110000-00006 · Cited by 494
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability
Wang, D., Johnson, A. D., Papp, A. C., Kroetz, D. L., & Sadée, W. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000178311.02878.83 · Cited by 490
Clinical consequences of cytochrome P450 2C9 polymorphisms
KIRCHHEINER, J., & BROCKMOLLER, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.009 · Cited by 474
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
Williams, J. A., Ring, B. J., Cantrell, V. E., Jones, D. R., Eckstein, J., Ruterbories, K., Hamman, M. A., Hall, S. D., & Wrighton, S. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.8.883 · Cited by 471
Schroth, W., Antoniadou, L., Fritz, P., Schwab, M., Muerdter, T., Zanger, U. M., Simon, W., Eichelbaum, M., & Brauch, H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2705 · Cited by 467
The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology
Kottra, G., & Daniel, H. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1101-4 · Cited by 466
Kimura, S., Umeno, M., Skoda, R. C., Meyer, U., & Gonzalez, F. J. (1989) · Europe PMC (PubMed Central) · Cited by 462
Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene
Mealey, K. L., Bentjen, S. A., Gay, J. M., & Cantor, G. H. (2001) · Pharmacogenetics · doi:10.1097/00008571-200111000-00012 · Cited by 454
Impact of P-glycoprotein on clopidogrel absorption
Taubert, D., VONBECKERATH, N., Grimberg, G., Lazar, A., JUNG, N., Goeser, T., Kastrati, A., Schömig, A., & Schömig, E. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.07.007 · Cited by 453
Nakamura, K., Goto, F., Ray, W. A., McAllister, C. B., Jacqz, E., Wilkinson, G. R., & Branch, R. A. (1985) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1985.194 · Cited by 452
Özdemir, V., KALOW, W., Tang, B.-K., Paterson, A. D., Walker, S. E., Endrényi, L., & Kashuba, A. D. M. (2000) · Pharmacogenetics · doi:10.1097/00008571-200007000-00001 · Cited by 440
BLUM, M., GRANT, D. M., McBRIDE, W., HEIM, M., & MEYER, U. A. (1990) · DNA and Cell Biology · doi:10.1089/dna.1990.9.193 · Cited by 435
Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin
Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., & Niemi, M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100220 · Cited by 432
Kirchheiner, J., Brøsen, K., Dahl, M. L., Gram, L. F., Kasper, S., Roots, I., Sjöqvist, F., Spina, E., & Brockmöller, J. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00299.x · Cited by 422
Niemi, M., Schaeffeler, E., Lang, T., Fromm, M. F., Neuvonen, M., Kyrklund, C., Backman, J. T., Kerb, R., Schwab, M., Neuvonen, P. J., et al. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114750.08559.32 · Cited by 418
Choudhuri, S., & Klaassen, C. D. (2006) · International Journal of Toxicology · doi:10.1080/10915810600746023 · Cited by 415
Sulfation and sulfotransferases 1: Sulfotransferase molecular biology: cDNAs and genes.
Weinshilboum, R. M., Otterness, D. M., Aksoy, I. A., Wood, T. C., Her, C., & Raftogianis, R. B. (1997) · PubMed · Cited by 408
Role of the breast cancer resistance protein (ABCG2) in drug transport
Mao, Q. (2005) · The AAPS Journal · doi:10.1208/aapsj070112 · Cited by 405
Evans, W. E., Hon, Y. Y., Bomgaars, L., Coutre, S., Holdsworth, M., Janco, R., Kalwinsky, D., Keller, F., Khatib, Z., Margolin, J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2293 · Cited by 400
Evans, W. E., Horner, M., Chu, Y. Q., Kalwinsky, D., & Roberts, W. M. (1991) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)83063-x · Cited by 392
Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms*
Otterness, D., Szumlanski, C., Lennard, L., Klemetsdal, B., Aarbakke, J., Park-Hah, J. O., Iven, H., Schmiegelow, K., Branum, E., O'Brien, J., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90152-1 · Cited by 390
Kadakol, A., Ghosh, S. S., Sappal, B. S., Sharma, G., Chowdhury, J. R., & Chowdhury, N. R. (2000) · Human Mutation · doi:10.1002/1098-1004(200010)16:4<297::aid-humu2>3.0.co;2-z · Cited by 387
Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man
K�pfer, A., & Preisig, R. (1984) · European Journal of Clinical Pharmacology · doi:10.1007/bf00541938 · Cited by 362
Holford, N. H. G. (1986) · Clinical Pharmacokinetics · doi:10.2165/00003088-198611060-00005 · Cited by 360
Evidence That CYP2C19 is the Major (S)-Mephenytoin 4'-Hydroxylase in Humans
Goldstein, J. A., Faletto, M. B., Romkes-Sparks, M., Sullivan, T., Kitareewan, S., Raucy, J. L., Lasker, J. M., & Ghanayem, B. I. (1994) · Biochemistry · doi:10.1021/bi00173a017 · Cited by 360
Bodin, L. (2005) · Blood · doi:10.1182/blood-2005-01-0341 · Cited by 360
NIEMI, M., BACKMAN, J., KAJOSAARI, L., LEATHART, J., NEUVONEN, M., DALY, A., EICHELBAUM, M., KIVISTO, K., & NEUVONEN, P. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.01.018 · Cited by 360
Comparison of 5-mg and 10-mg Loading Doses in Initiation of Warfarin Therapy
Harrison, L., Johnston, M., Massicotte, M. P., Crowther, M., Moffat, K., & Hirsh, J. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-2-199701150-00006 · Cited by 359
Pharmacogenomics of human OATP transporters
König, J., Seithel, A., Gradhand, U., & Fromm, M. F. (2006) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-006-0040-y · Cited by 357
ROLE OF ABCG2/BCRP IN BIOLOGY AND MEDICINE
Krishnamurthy, P., & Schuetz, J. D. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141238 · Cited by 356
Goldstein, J. A., Ishizaki, T., Chiba, K., de Morais, S. M. F., Bell, D., Krahn, P. M., & Price Evans, D. A. (1997) · Pharmacogenetics · doi:10.1097/00008571-199702000-00008 · Cited by 350
Scordo, M. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.129321 · Cited by 344
CYP2C9 allelic variants: ethnic distribution and functional significance
Xie, H.-G., Prasad, H. C., Kim, R. B., & Stein, C. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00076-5 · Cited by 338
HUMAN FLAVIN-CONTAINING MONOOXYGENASES
Cashman, J. R., & Zhang, J. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141043 · Cited by 333
TENHUNEN, J., SALMINEN, M., LUNDSTRÖM, K., KIVILUOTO, T., SAVOLAINEN, R., & ULMANEN, I. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.tb19083.x · Cited by 331
Breedveld, P., Beijnen, J. H., & Schellens, J. H. M. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.009 · Cited by 323
Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
Eby, C., Milligan, P. E., Banet, G. A., Duncan, J., McLeod, H. L., & Gage, B. F. (2003) · Thrombosis and Haemostasis · doi:10.1160/th03-06-0379 · Cited by 322
A proposed nomenclature system for the cytosolic sulfotransferase (SULT) superfamily
Blanchard, R. L., Freimuth, R. R., Buck, J., Weinshilboum, R. M., & Coughtrie, M. W. (2004) · Pharmacogenetics · doi:10.1097/00008571-200403000-00009 · Cited by 320
Cytochrome P4503A (CYP3A) metabolism: Prediction ofIn Vivo activity in humans
Wilkinson, G. R. (1996) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf02353475 · Cited by 311
Krynetski, E. Y., Schuetz, J. D., Galpin, A. J., Pui, C. H., Relling, M. V., & Evans, W. E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.4.949 · Cited by 306
Raftogianis, R. B., Wood, T. C., Otterness, D. M., Van Loon, J. A., & Weinshilboum, R. M. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7466 · Cited by 305
SZUMLANSKI, C., OTTERNESS, D., HER, C., LEE, D., BRANDRIFF, B., KELSELL, D., SPURR, N., LENNARD, L., WIEBEN, E., & WEINSHILBOUM, R. (1996) · DNA and Cell Biology · doi:10.1089/dna.1996.15.17 · Cited by 305
Genetic association between sensitivity to warfarin and expression of CYP2C9*3
Steward, D. J., Haining, R. L., Henne, K. R., Davis, G., Rushmore, T. H., Trager, W. F., & Rettie, A. E. (1997) · Pharmacogenetics · doi:10.1097/00008571-199710000-00004 · Cited by 303
Genetic analysis of the human cytochrome P450 CYP2C9 locus
Stubbins, M. J., Harries, L. W., Smith, G., Tarbit, M. H., & Wolf, C. R. (1996) · Pharmacogenetics · doi:10.1097/00008571-199610000-00007 · Cited by 300
Leschziner, G. D., Andrew, T., Pirmohamed, M., & Johnson, M. R. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500413 · Cited by 300
Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
Mwinyi, J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.016 · Cited by 293
Complete Characterization of the Human ABC Gene Family
Dean, M., & Allikmets, R. (2001) · Journal of Bioenergetics and Biomembranes · doi:10.1023/a:1012823120935 · Cited by 289
Li, X.-Q., Björkman, A., Andersson, T. B., Ridderström, M., & Masimirembwa, C. M. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.2.399 · Cited by 288
Shu, Y., Leabman, M. K., Feng, B., Mangravite, L. M., Huang, C. C., Stryke, D., Kawamoto, M., Johns, S. J., DeYoung, J., Carlson, E., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730858100 · Cited by 285
Wrighton, S. A., Stevens, J. C., Becker, G. W., & Vandenbranden, M. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1506 · Cited by 281
Bernard, S., Neville, K. A., Nguyen, A. T., & Flockhart, D. A. (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-126 · Cited by 277
Polymorphism of the thiopurine S-methyltransferase gene in African- Americans
Hon, Y. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.2.371 · Cited by 271
Klein, K., Lang, T., Saussele, T., Barbosa-Sicard, E., Schunck, W.-H., Eichelbaum, M., Schwab, M., & Zanger, U. M. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200512000-00004 · Cited by 269
Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase.
Weinshilboum, R. M. (2001) · PubMed · Cited by 269
Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence*
Malaiyandi, V., Sellers, E. M., & Tyndale, R. F. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.10.011 · Cited by 267
Backman, J. T., Kivistö, K. T., Olkkola, K. T., & Neuvonen, P. J. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050420 · Cited by 266
Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males
Zhang, W., Yu, B.-N., He, Y.-J., Fan, L., Li, Q., Liu, Z.-Q., Wang, A., Liu, Y.-L., Tan, Z.-R., Fen-Jiang, et al. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2006.05.010 · Cited by 263
Carlini, L. E., Meropol, N. J., Bever, J., Andria, M. L., Hill, T., Gold, P., Rogatko, A., Wang, H., & Blanchard, R. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1226.11.3 · Cited by 262
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man
Breckenridge, A., Orme, M., Wesseling, H., Lewis, R. J., & Gibbons, R. (1974) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1974154424 · Cited by 261
CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates
Takanashi, K., Tainaka, H., Kobayashi, K., Yasumori, T., Hosakawa, M., & Chiba, K. (2000) · Pharmacogenetics · doi:10.1097/00008571-200003000-00001 · Cited by 261
Interindividual variability in sensitivity to warfarin-Nature or nurture?
Loebstein, R. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.117444 · Cited by 260
Geisen, C., Watzka, M., Sittinger, K., Steffens, M., Daugela, L., Seifried, E., Müller, C. R., Wienker, T. F., & Oldenburg, J. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-04-0290 · Cited by 259
Tai, H.-L., Krynetski, E. Y., Schuetz, E. G., Yanishevski, Y., & Evans, W. E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6444 · Cited by 259
Irinotecan pathway genotype analysis to predict pharmacokinetics.
Mathijssen, R. H. J., Marsh, S., Karlsson, M. O., Xie, R., Baker, S. D., Verweij, J., Sparreboom, A., & McLeod, H. L. (2003) · PubMed · Cited by 258
SAI, K. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.01.010 · Cited by 257
Dawling, S., Roodi, N., Mernaugh, R. L., Wang, X., & Parl, F. F. (2001) · PubMed · Cited by 250
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
NIEMI, M., PASANEN, M., & NEUVONEN, P. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.06.010 · Cited by 250
Fang, M. C., Go, A. S., Hylek, E. M., Chang, Y., Henault, L. E., Jensvold, N. G., & Singer, D. E. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2006.00828.x · Cited by 249
Bertilsson, L., Henthorn, T. K., Sanz, E., Tybring, G., Säwe, J., & Villén, T. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.40 · Cited by 249
Validation of Methods for CYP2C9 Genotyping: Frequencies of Mutant Alleles in a Swedish Population
Yasar, Ü., Eliasson, E., Dahl, M.-L., Johansson, I., Ingelman-Sundberg, M., & Sjöqvist, F. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9992 · Cited by 249
Dickmann, L. J., Rettie, A. E., Kneller, M. B., Kim, R. B., Wood, A. J. J., Stein, C. M., Wilkinson, G. R., & Schwarz, U. I. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23142-4 · Cited by 249
Limdi, N., McGwin, G., Goldstein, J., Beasley, T., Arnett, D., Adler, B., Baird, M., & Acton, R. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100290 · Cited by 248
Inheritance of low erythrocyte catechol-o-methyltransferase activity in man.
Weinshilboum, R. M., & Raymond, F. A. (1977) · Europe PMC (PubMed Central) · Cited by 247
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype*1
SPARREBOOM, A. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.03.003 · Cited by 241
Identification of a null allele of CYP2C9 in an African–American exhibiting toxicity to phenytoin
Kidd, R. S., Curry, T. B., Gallagher, S., Edeki, T., Blaisdell, J., & Goldstein, J. A. (2001) · Pharmacogenetics · doi:10.1097/00008571-200112000-00008 · Cited by 236
Rudberg, I., Mohebi, B., Hermann, M., Refsum, H., & Molden, E. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100291 · Cited by 232
Identification of Human Liver Cytochrome P450 Isoforms Mediating Omeprazole Metabolism
ANDERSSON, T., MINERS, J. O., VERONESE, M. E., TASSANEEYAKUL, W., TASSANEEYAKUL, W., MEYER, U. A., & BIRKETT, D. J. (1993) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1993.tb00410.x · Cited by 230
Giusti, B., Gori, A. M., Marcucci, R., Saracini, C., Sestini, I., Paniccia, R., Valente, S., Antoniucci, D., Abbate, R., & Gensini, G. F. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f1b2be · Cited by 230
Identification of a polymorphically expressed member of the human cytochrome P-450III family.
Wrighton, S. A., Ring, B. J., Watkins, P. B., & VandenBranden, M. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09114-x · Cited by 228
Andersson, T., Miners, J., Veronese, M., & Birkett, D. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04336.x · Cited by 225
Cytochrome P450 2C8: Substrates, inhibitors, pharmacogenetics, and clinical relevance
TOTAH, R., & RETTIE, A. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.12.267 · Cited by 225
P-Glycoprotein Recognition of Substrates and Circumvention through Rational Drug Design
Raub, T. J. (2006) · Molecular Pharmaceutics · doi:10.1021/mp0500871 · Cited by 221
Implications of genetic polymorphisms in drug transporters for pharmacotherapy
Kerb, R. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.06.051 · Cited by 219
Meier, Y., Pauli-Magnus, C., Zanger, U. M., Klein, K., Schaeffeler, E., Nussler, A. K., Nussler, N., Eichelbaum, M., Meier, P. J., & Stieger, B. (2006) · Hepatology · doi:10.1002/hep.21214 · Cited by 219
Kerb, R., Brinkmann, U., Chatskaia, N., Gorbunov, D., Gorboulev, V., Mornhinweg, E., Keil, A., Eichelbaum, M., & Koepsell, H. (2002) · Pharmacogenetics · doi:10.1097/00008571-200211000-00002 · Cited by 214
THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS*
WRIGHTON, S. A., SCHUETZ, E. G., THUMMEL, K. E., SHEN, D. D., KORZEKWA, K. R., & WATKINS, P. B. (2000) · Drug Metabolism Reviews · doi:10.1081/dmr-100102338 · Cited by 213
Sindrup, S. H., Brøsen, K., Hansen, M. G. J., Aaes-Jørgensen, T., Overø, K. F., & Gram, L. F. (1993) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199302000-00002 · Cited by 213
Geisler, T., Schaeffeler, E., Dippon, J., Winter, S., Buse, V., Bischofs, C., Zuern, C., Moerike, K., Gawaz, M., & Schwab, M. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.9.1251 · Cited by 213
Organic Anion Transporter Family: Current Knowledge
Anzai, N., Kanai, Y., & Endou, H. (2006) · Journal of Pharmacological Sciences · doi:10.1254/jphs.crj06006x · Cited by 209
Kirchheiner, J., Roots, I., Goldammer, M., Rosenkranz, B., & Brockm??ller, J. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544120-00002 · Cited by 204
Human phenol sulfotransferases SULT1A2 and SULT1A1
Raftogianis, R. B., Wood, T. C., & Weinshilboum, R. M. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00145-8 · Cited by 197
Thompson, J. F., Hyde, C. L., Wood, L. S., Paciga, S. A., Hinds, D. A., Cox, D. R., Hovingh, G. K., & Kastelein, J. J. P. (2009) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.108.818062 · Cited by 195
Pharmacogenetics of oral anticoagulants
Daly, A. K., & King, B. P. (2003) · Pharmacogenetics · doi:10.1097/00008571-200305000-00002 · Cited by 195
CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis
Vuilleumier, N., Rossier, M. F., Chiappe, A., Degoumois, F., Dayer, P., Mermillod, B., Nicod, L., Desmeules, J., & Hochstrasser, D. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0111-5 · Cited by 191
Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function
Leabman, M. K., Huang, C. C., Kawamoto, M., Johns, S. J., Stryke, D., Ferrin, T. E., DeYoung, J., Taylor, T., Clark, A. G., Herskowitz, I., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200207000-00007 · Cited by 191
Pharmacogenetics of the arylamine N-acetyltransferases
Butcher, N. J., Boukouvala, S., Sim, E., & Minchin, R. F. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500053 · Cited by 190
Raimundo, S., Fischer, J., Eichelbaum, M., Griese, E.-U., Schwab, M., & Zanger, U. M. (2000) · Pharmacogenetics · doi:10.1097/00008571-200010000-00001 · Cited by 189
Choudhry, N. K., Anderson, G. M., Laupacis, A., Ross-Degnan, D., Normand, S.-L. T., & Soumerai, S. B. (2006) · BMJ · doi:10.1136/bmj.38698.709572.55 · Cited by 186
Takahashi, H., Kashima, T., Nomizo, Y., Muramoto, N., Shimizu, T., Nasu, K., Kubota, T., Kimura, S., & Echizen, H. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90103-5 · Cited by 183
GARCIAMARTIN, E. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.04.006 · Cited by 182
Cloning and Tissue Distribution of a Novel Human Cytochrome P450 of the CYP3A Subfamily, CYP3A43
Westlind, A., Malmebo, S., Johansson, I., Otter, C., Andersson, T. B., Ingelman-Sundberg, M., & Oscarson, M. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4505 · Cited by 178
Genetic-based dosing in orthopedic patients beginning warfarin therapy
Millican, E. A., Lenzini, P. A., Milligan, P. E., Grosso, L., Eby, C., Deych, E., Grice, G., Clohisy, J. C., Barrack, R. L., Burnett, R. S. J., et al. (2007) · Blood · doi:10.1182/blood-2007-01-069609 · Cited by 178
Venkatakrishnan, K., Greenblatt, D. J., Moltke, L. L., Schmider, J., Harmatz, J. S., & Shader, R. I. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04399.x · Cited by 175
Yamazaki, H., Inoue, K., Chiba, K., Ozawa, N., Kawai, T., Suzuki, Y., Goldstein, J. A., Guengerich, F. P., & Shimada, T. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00133-6 · Cited by 172
Iakoubova, O. A., Tong, C. H., Rowland, C. M., Kirchgessner, T. G., Young, B. A., Arellano, A. R., Shiffman, D., Sabatine, M. S., Campos, H., Packard, C. J., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.05.057 · Cited by 171
RAU, T., Erney, B., Göres, R., Thomas Eschenhagen, A., BECK, J., & Langer, T. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.08.012 · Cited by 171
Spire‐Vayron de la Moureyre, C., Debuysere, H., Mastain, B., Vinner, E., Marez, D., Lo Guidice, J., Chevalier, D., Brique, S., Motte, K., Colombel, J., et al. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702152 · Cited by 170
Effect of () variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers
CHUNG, J., CHO, J., YU, K., KIM, J., OH, D., JUNG, H., LIM, K., MOON, K., SHIN, S., & JANG, I. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.07.003 · Cited by 170
Bosch, T. M., Meijerman, I., Beijnen, J. H., & Schellens, J. H. M. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645030-00003 · Cited by 167
Holthe, M., Rakvåg, T. N., Klepstad, P., Idle, J. R., Kaasa, S., Krokan, H. E., & Skorpen, F. (2003) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500139 · Cited by 163
Nowell, S. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.21.1635 · Cited by 160
Polymorphism in KIF6 Gene and Benefit From Statins After Acute Coronary Syndromes
Iakoubova, O. A., Sabatine, M. S., Rowland, C. M., Tong, C. H., Catanese, J. J., Ranade, K., Simonsen, K. L., Kirchgessner, T. G., Cannon, C. P., Devlin, J. J., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.017 · Cited by 159
Pharmacogenetics of human cytosolic sulfotransferases
Nowell, S., & Falany, C. N. (2006) · Oncogene · doi:10.1038/sj.onc.1209376 · Cited by 158
Holstein, A., Plaschke, A., Ptak, M., Egberts, E. ‐., El-Din, J. S., Brockmöller, J., & Kirchheiner, J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02379.x · Cited by 155
Furuta, T., Shirai, N., Watanabe, F., Honda, S., Takeuchi, K., Iida, T., Sato, Y., Kajimura, M., Futami, H., Takayanagi, S., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127637 · Cited by 153
Shield, A., Thomae, B. A., Eckloff, B. W., Wieben, E. D., & Weinshilboum, R. M. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001386 · Cited by 153
Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests
ANDERSSON, T., Flockhart, D. A., Goldstein, D. A., Huang, S. M., Kroetz, D. L., Milos, P. M., Ratain, M. J., & Thummel, K. E. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.08.013 · Cited by 153
Organic anion transporter (Slc22a) family members as mediators of toxicity
Sweet, D. H. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.10.016 · Cited by 150
Kaskas, B., Louis, E., Hindorf, U., Schaeffeler, E., Deflandre, J., Graepler, F., Schmiegelow, K., Gregor, M., Zanger, U. M., Eichelbaum, M., et al. (2002) · Gut · doi:10.1136/gut.52.1.140 · Cited by 150
Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
Wang, J., Liu, Z., Wang, W., Chen, X., Shu, Y., He, N., & Zhou, H. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.116513 · Cited by 147
Nagar, S., WALTHER, S. E., & Blanchard, R. L. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.019240 · Cited by 147
Strassburg, C. P., Nguyen, N. T., Manns, M. P., & Tukey, R. H. (1998) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)13065-9 · Cited by 146
Carlini, E. J., Raftogianis, R. B., Wood, T. C., Jin, F., Zheng, W., Rebbeck, T. R., & Weinshilboum, R. M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200102000-00007 · Cited by 145
Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype
Hillman, M. A., Wilke, R. A., Caldwell, M. D., Berg, R. L., Glurich, I., & Burmester, J. K. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114760.08559.dc · Cited by 144
Functional Implications of Genetic Polymorphisms in the Multidrug Resistance Gene MDR1 (ABCB1)
Pauli-Magnus, C., & Kroetz, D. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000029276.21063.0b · Cited by 144
Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms
Yaşar, Ü., Lundgren, S., Eliasson, E., Bennet, A. M., Wiman, B., Fairé, U. D., & Rane, A. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02592-5 · Cited by 143
Discovery of new potentially defective alleles of human CYP2C9
Blaisdell, J. A., Jorge-Nebert, L. F., Coulter, S. J., Ferguson, S., Lee, S., Chanas, B., Xi, T., Mohrenweiser, H. W., Ghanayem, B. I., & Goldstein, J. A. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114759.08559.51 · Cited by 142
A single-nucleotide polymorphism tagging set for human drug metabolism and transport
Ahmadi, K. R., Weale, M. E., Xue, Z., Soranzo, N., Yarnall, D. P., Briley, J. D., Maruyama, Y., Kobayashi, M., Wood, N. W., Spurr, N. K., et al. (2004) · Nature Genetics · doi:10.1038/ng1488 · Cited by 142
A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination
Hulot, J., Villard, E., Maguy, A., Morel, V., Mir, L. M., Tostivint, I. N., Faltaos, D. W., Fernandez, C., Hatem, S. N., Deray, G., et al. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200505000-00002 · Cited by 141
Hamberg, A., Dahl, M.-L., Barban, M., Scordo, M. G., Wadelius, M., Pengo, V., Padrini, R., & Jonsson, E. N. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100084 · Cited by 141
Sakakibara, Y., Yanagisawa, K., Katafuchi, J., Ringer, D. P., Takami, Y., Nakayama, T., Suiko, M., & Liu, M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.51.33929 · Cited by 136
Niemi, M., Kivistö, K. T., Hofmann, U., Schwab, M. G., Eichelbaum, M. F., & Fromm, M. F. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02354.x · Cited by 135
Ingelman‐Sundberg, M., & Rodríguez‐Antona, C. (2005) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2005.1685 · Cited by 134
Pharmacogenetics of the Cytochromes P450
Daly, A. K. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043387070 · Cited by 133
Takahashi, H. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.110977 · Cited by 133
Fujita, T., Urban, T., Leabman, M. K., et al. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20536 · Cited by 133
Identification and functional characterization of new potentially defective alleles of human CYP2C19
Blaisdell, J. A., Mohrenweiser, H. W., Jackson, J., Ferguson, S., Coulter, S. J., Chanas, B., Xi, T., Ghanayem, B. I., & Goldstein, J. A. (2002) · Pharmacogenetics · doi:10.1097/00008571-200212000-00004 · Cited by 132
He, P., Court, M. H., Greenblatt, D. J., & VONMOLTKE, L. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.11.112 · Cited by 132
Imai, J., Ieiri, I., Mamiya, K., et al. (2000) · Pharmacogenetics · doi:10.1097/00008571-200002000-00011 · Cited by 131
Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use
Martínez, C., Blanco‐Fernández, G., Ladero, J. M., García‐Martín, E., Taxonera, C., Garcia-Gamito, F. J., Díaz‐Rubio, M., & Agúndez, J. A. G. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705623 · Cited by 130
Genetics of the Variable Expression of CYP3A in Humans
Wojnowski, L. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200404000-00019 · Cited by 129
Cited by
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809329 · Cited by 1,577
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Evidence-Based Management of Anticoagulant Therapy
Holbrook, A., Schulman, S., Witt, D. M., Vandvik, P. O., Fish, J., Kovacs, M. J., Svensson, P. J., Veenstra, D. L., Crowther, M., & Guyatt, G. H. (2012) · Chest · doi:10.1378/chest.11-2295 · Cited by 1,269
Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin
Gage, B., Eby, C., Johnson, J., Deych, E., Rieder, M., Ridker, P., Milligan, P., Grice, G., Lenzini, P., Rettie, A., et al. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.10 · Cited by 847
A Randomized Trial of Genotype-Guided Dosing of Warfarin
Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., Nicholson, T., Kesteven, P., Christersson, C., Wahlström, B., Stafberg, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311386 · Cited by 811
Metadata
- Authors
- Caraco, Y., Blotnick, S., & Muszkat, M.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2007-09-12
- Volume
- 83
- Issue
- 3
- Pages
- 460-470
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2032289591
- Cited by
- 360
- References
- 279
- FWCI
- 35.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.